<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A — News on 6ix</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a</link>
<description>Latest news and press releases for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 16:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dizal-jiangsu-pharmaceutical-co-ltd-a" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836469278dffbe2df1515ac.webp</url>
<title>Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a</link>
</image>
<item>
<title>Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-to-report-key-progress-in-its-nsclc-portfolio-with-two-oral-presentations-and-a-poster-during-asco-2026</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-to-report-key-progress-in-its-nsclc-portfolio-with-two-oral-presentations-and-a-poster-during-asco-2026</guid>
<pubDate>Tue, 21 Apr 2026 16:45:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced that new clinical data from its non-small cell lung cancer (NSCLC) pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago. The presentations will feature the company's investigational assets ZEGFROVY® (sunvozertinib), golidocitinib, and DZD6008, highlighted by two oral pres</description>
</item>
<item>
<title>Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-showcases-strong-hematology-pipeline-100000967</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-showcases-strong-hematology-pipeline-100000967</guid>
<pubDate>Tue, 09 Dec 2025 10:00:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma.</description>
</item>
<item>
<title>The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/u-fda-granted-fast-track-110200260</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/u-fda-granted-fast-track-110200260</guid>
<pubDate>Wed, 06 Aug 2025 11:02:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor</description>
</item>
<item>
<title>Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizals-zegfrovy-sunvozertinib-receives-fda-000800222</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizals-zegfrovy-sunvozertinib-receives-fda-000800222</guid>
<pubDate>Thu, 03 Jul 2025 00:08:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved ZEGFROVY® (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has prog</description>
</item>
<item>
<title>Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-completes-enrollment-phase-iii-100800587</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-completes-enrollment-phase-iii-100800587</guid>
<pubDate>Thu, 19 Jun 2025 10:08:00 GMT</pubDate>
<description>Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).</description>
</item>
<item>
<title>Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-showcases-two-first-class-101300166</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-showcases-two-first-class-101300166</guid>
<pubDate>Thu, 12 Jun 2025 10:13:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present research findings on two of its first-in-class hematologic oncology assets—golidocitinib and DZD8586—at the 2025 European Hematology Association (EHA) Annual Congress and the 18th International Conference on Malignant Lymphoma (ICML). These include long-term follow-up data on golidocitinib as a maintenance therapy in periph</description>
</item>
<item>
<title>Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-highlight-portfolio-advances-hematologic-100500769</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-highlight-portfolio-advances-hematologic-100500769</guid>
<pubDate>Mon, 26 May 2025 10:05:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical study results of its investigational drugs DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies focus on B-cell non-Hodgkin lymphomas (B-NHLs) and non-small cell lung cancer (NSCLC) two disease areas Dizal has approved drugs and strong clinical pipeli</description>
</item>
<item>
<title>Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-present-promising-clinical-data-100900467</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-present-promising-clinical-data-100900467</guid>
<pubDate>Thu, 15 May 2025 10:09:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the latest data from eight hematologic malignancy clinical trials will be presented at the 2025 European Hematology Association (EHA) Congress and the 18th International Conference on Malignant Lymphoma (ICML). Notably, Dizal's two investigational drugs in lymphoma—golidocitinib and DZD8586—have collectively secured three oral presentation</description>
</item>
<item>
<title>Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-showcase-data-hematologic-malignancies-103800323</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-showcase-data-hematologic-malignancies-103800323</guid>
<pubDate>Thu, 24 Apr 2025 10:38:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will feature the latest study results from the company's investigational drugs DZD8586 and DZD6008 in B-cell non-Hodgkin lymphomas (B-NHLs) and non-small cell lung cancer (NSCLC).</description>
</item>
<item>
<title>Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-announces-dzd8586-dzd6008-presentations-101800944</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizal-announces-dzd8586-dzd6008-presentations-101800944</guid>
<pubDate>Tue, 01 Apr 2025 10:18:00 GMT</pubDate>
<description>Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidates DZD8586 and DZD6008, have been selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3, 2025, in Chicago.</description>
</item>
<item>
<title>Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizals-golidocitinib-combination-anti-pd-100000684</link>
<guid isPermaLink="true">https://6ix.com/company/dizal-jiangsu-pharmaceutical-co-ltd-a/news/dizals-golidocitinib-combination-anti-pd-100000684</guid>
<pubDate>Thu, 20 Mar 2025 10:00:00 GMT</pubDate>
<description>Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, today announced new findings on golidocitinib, a first-in-class Janus kinase 1 (JAK1) only inhibitor, in combination with PD-1 antibodies for patients who have progressed on anti-PD-1 therapy. The details of the trial design and clinical results will be presented at the 2025 European Lung Cancer Congress (ELCC 2025) in Paris, March 26-29.</description>
</item>
</channel>
</rss>